J.D., M.B.A., Co-Founder & CEO, Paradigm Diagnostics
David Mallery is the Co-Founder and CEO of Paradigm Diagnostics. Mr. Mallery was also the Co-Founder, President and a Director of the Molecular Profiling Institute and its subsidiary the Tissue Banking and Analysis Center (a joint venture with US Oncology/McKesson) which was acquired by Caris Life Sciences. Mr. Mallery also helped co-found and serves as President of the International Genomics Consortium (IGC) and helped lead efforts to land and expand IGC’s role as the founding Biospecimen Core Resource and Tissue Source Site network for the National Cancer Institute’s flagship project – The Cancer Genome Atlas (TCGA). He was formerly the Principal Venture Analyst for the Calvert Group’s venture and equity fund investments and has been an investment advisor on numerous biotech investments through exit. Mr. Mallery is an active member of YPO, a life member of the Council on Foreign Relations and a member of the Colorado Bar Association and the District of Columbia Bar Association. Mr. Mallery has a JD and MBA from the University of Colorado at Boulder and a BA from Stanford University in Art Studio: Design and Human Biology.
Presentation Title and Company Description
Clinical Dx Showcase: Accurate, Comprehensive and Actionable = Improved Outcomes
Paradigm Diagnostics offers accurate, comprehensive and clinically actionable cancer genomic profiling and therapeutic information, in an average of 5 business days to better support patient care. The Paradigm Cancer Diagnostic (PCDx) comprehensive sequencing test analyzes DNA, RNA, Fusions, and Protein by immunohistochemisty to provide treating physicians and patients with more precise information about the specific cancer pathways in the tumor to allow for more effective decision-making.